HJ-119

HJ-119: sourced facts only. name: "We developed a novel, highly selective, orally bioavailable small molecule inhibitor of KRASG12D, denoted as HJ-119, and evaluated its antitumor activities in both in vitro and in vivo studies." [DOI:10.1158/1538-7445.am2025-4390]; target: "We developed a novel, highly selective, orally bioavailable small molecule inhibitor of KRASG12D, denoted as HJ-119, and evaluated its antitumor activities in both in vitro and in vivo studies." [DOI:10.1158/1538-7445.am2025-4390]; developer: "Chengdu Huajian Science Co., Ltd., Chengdu, China." [DOI:10.1158/1538-7445.am2025-4390]; modality: "We developed a novel, highly selective, orally bioavailable small molecule inhibitor of KRASG12D, denoted as HJ-119, and evaluated its antitumor activities in both in vitro and in vivo studies." [DOI:10.1158/1538-7445.am2025-4390]; stage: "Consistent with the in vitro data, in AsPC-1 xenograft mouse model, tumor growth was significantly inhibited after HJ-119 treated and favorable safety profile was presented." [DOI:10.1158/1538-7445.am2025-4390]